| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.25▼ | 1.25▼ | 1.26▼ | 1.29▼ | 1.28▼ |
| MA10 | 1.27▼ | 1.29▼ | 1.29▼ | 1.27▼ | 1.23▲ |
| MA20 | 1.29▼ | 1.28▼ | 1.29▼ | 1.29▼ | 1.29▼ |
| MA50 | 1.28▼ | 1.26▼ | 1.26▼ | 1.25▼ | 1.53▼ |
| MA100 | 1.26▼ | 1.27▼ | 1.28▼ | 1.31▼ | 3.10▼ |
| MA200 | 1.28▼ | 1.26▼ | 1.24▼ | 1.41▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.011▼ | -0.011▼ | -0.010▼ | -0.005▼ | 0.037▲ |
| RSI | 37.194▼ | 41.922▼ | 40.955▼ | 45.603▼ | 42.161▼ |
| STOCH | 12.923▼ | 21.044 | 32.155 | 75.639 | 55.076 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -48.000 | -59.091 |
| CCI | -123.003▼ | -106.601▼ | -147.234▼ | -68.489 | 12.744 |
|
Wednesday, April 01, 2026 01:18 PM
First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a ...
|
|
Saturday, February 14, 2026 12:32 PM
MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing small-molecule ...
|
|
Saturday, December 20, 2025 02:02 PM
MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing therapies that target ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/04/26 | 1.25 | 1.27 | 1.23 | 1.23 | 45,257 |
| 09/04/26 | 1.30 | 1.33 | 1.24 | 1.26 | 67,286 |
| 08/04/26 | 1.32 | 1.35 | 1.30 | 1.33 | 52,002 |
| 07/04/26 | 1.27 | 1.32 | 1.23 | 1.32 | 44,818 |
| 06/04/26 | 1.25 | 1.30 | 1.25 | 1.30 | 25,707 |
| 02/04/26 | 1.31 | 1.33 | 1.25 | 1.27 | 87,415 |
| 01/04/26 | 1.265 | 1.34 | 1.25 | 1.32 | 87,107 |
| 31/03/26 | 1.18 | 1.30 | 1.1605 | 1.30 | 110,764 |
| 30/03/26 | 1.24 | 1.255 | 1.10 | 1.14 | 125,123 |
| 27/03/26 | 1.25 | 1.26 | 1.21 | 1.25 | 82,006 |
|
|
||||
|
|
||||
|
|